Vertex cystic fibrosis combo meets study goals

June 24, 2014 11:02 AM

9 0

Vertex cystic fibrosis combo meets study goals

The studies, which ran for 24 weeks, also met secondary goals, including reducing pulmonary exacerbations — or signs of the disease worsening and requiring treatment with antibiotics — and helping patients gain weight, Vertex said. The trials were conducted in more than 1,100 patients age 12 and older with two copies of a mutation known as F508del.

"On average, people with cystic fibrosis who have two copies of the F508del mutation lose nearly two percent of their lung function each year, underscoring the urgent need for new medicines that address the underlying cause of this disease," Bonnie Ramsey, professor of pediatrics at the University o...

Read more

To category page